Janux Therapeutics Inc
NASDAQ:JANX
Janux Therapeutics Inc
NASDAQ:JANX
Price:
56.08 USD
18.34%
Market Closed
Updated:
Apr 30, 2024
Section:
Relative Value
The Relative Value of one
JANX
stock under the Base Case scenario is
2.22
USD.
Compared to the current market price of 56.08 USD,
Janux Therapeutics Inc
is
Overvalued by 96%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
JANX
Relative Value
Base Case
2.22
USD
Overvaluation 96%
Valuation Multiples
Multiples Across Competitors
JANX Competitors Multiples
Janux Therapeutics Inc Competitors
Janux Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Janux Therapeutics Inc
NASDAQ:JANX
|
2.9B USD | 358.4 | -49.7 | -35.9 | -35 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.2B USD | 5.3 | 59.2 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148B USD | 5.2 | 22 | 16.4 | 24.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.1B USD | 10.3 | 28.2 | 22.5 | 23.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.6B USD | 7.4 | 24.7 | 16.3 | 17.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.9B AUD | 6.2 | 35.3 | 21.4 | 26.5 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.2B USD | 3 | 14.5 | 8 | 10.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.6 | -8.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.2B USD | 3.2 | 26.9 | 14.5 | 18 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.3T KRW | 18.1 | 73.5 | 45 | 61.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
